Skip to content

Open D3 Right Hemicolectomy Compared to Laparoscopic CME for Right Sided Colon Cancer

Open D3 Right Colectomy Compared to Laparoscopic CME Right Colectomy for Right Sided Colon Cancer; an Open Randomized Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03776591
Acronym
D3/CME
Enrollment
128
Registered
2018-12-14
Start date
2016-09-01
Completion date
2026-12-31
Last updated
2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulating Tumor Cell, Complication, Lymph Node Metastases, Quality of Life, Surgical Procedure, Unspecified

Keywords

D3 lymphadenectomy, Right-sided, Colon cancer, Complications, Circulating tumor cells, Circulating DNA (cDNA), Laparoscopy, Complete mesocolic excision

Brief summary

The primary focus in this study is to investigate and improve the surgical technique. In addition the collection of clinical data during diagnostic and follow up and the collection of tumor and blood gives us the opportunity to investigate tumor biology and its relevance in terms of determine appropriate treatment strategy both surgically and oncological and to assess and predict treatment outcome. The aim of this study is to compare short and long-term outcomes between open D3 and laparoscopic CME (complete mesocolic excision) with CVL (central vascular ligation) right colectomy for right-sided colon cancer. Our primary hypothesis is that laparoscopic surgery improves quality of life by reducing pain, postoperative complications and thereby reduces hospital stay and convalescence. On the other hand it is to prove non-inferiority of the laparoscopic group compared to the open group by means of oncological outcome (survival, recurrence). Secondary aim is to evaluate surgical quality by comparing actual vascular stump length between the two groups by postoperative CT and compare number of lymph nodes removed with the specimen. With the use of liquid biopsy we want to detect circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) and evaluate their value as tumor markers by comparing the prognostic and predictive value. The hypothesis is that ctDNA and CTCs are more sensitive than standard parameters and imaging (CT CEA).

Detailed description

This is a prospective, randomized, multi-center clinical study. The short term outcome, 2 and 5 year survival and mortality rates will be compared between the groups operated with open D3 resection at Haukeland University hospital and laparoscopic CME with CVL right hemicolectomy at Haraldsplass Deaconess hospital. Computer generated block randomization will be used. All patients ≤ 85 years with tumor localized in the right colon will be considered to participate in the study. The patients will be summoned to the first consultation to the hospital they are referred to. They will be informed of the study. A patient who meets the inclusion criteria will be asked to participate in the study and sign the informed consent. A patient who accepts will be assigned a sequential participant number and then referred to open D3 or laparoscopic CME (right hemicolectomy) according to a pre-specified randomized list of treatments. All patients referred with right sided colon cancer in the inclusion period will be registered, and the reason why some do not participate in the study will be documented. Patients who decline to participate in the study will be assigned standard treatment in the institution they are referred to. Blood samples for analysis of ctDNA/CTCs will be collected preoperatively, 3-10th postoperative day, at 3 months and at each check the next five years at six months intervals. All sample times except the first postoperative control, correspond to the time of CEA and CT in ordinary follow-up. Proteomic technology based analysis of tumor tissue

Interventions

PROCEDUREOpen surgery
PROCEDURELaparoscopic surgery
PROCEDURECentral lymphadenectomy and vascular ligation

Sponsors

Haraldsplass Deaconess Hospital
Lead SponsorOTHER
Helse-Bergen HF
CollaboratorOTHER
University of Bergen
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* • Patients with malignant tumor of the right colon (cecum, ascending colon, right flexure and right transverse) at CT, colonoscopy. * Patients medically cleared by anesthesiologist for general anesthesia and oncological radical resection * Patients ≤ 85 years * Signed informed consent form

Exclusion criteria

* • Patients with recurrent cancer after previous surgery * Patients with synchronous distant metastasis * Patients with ongoing oncological treatment due to other cancer

Design outcomes

Primary

MeasureTime frameDescription
Complications30 daysSurgical and general complications by Clavien-Dindo Classification og surgical complications

Secondary

MeasureTime frameDescription
Surgical quality vascular resection6 monthsVascular stump length in mm
Surgical quality lymph nodes6 monthsNumber of lymph nodes
Patient outcome general6 months15D Health-related quality of life (HRQoL) preoperative and at 6 months. Scale 0-1. a higher score reflects a better HRQoL
Patient outcome bowel function6 monthsQuality of life (LARS (low anterior resection syndrome) score preoperative and at 6 months. Scale 0-42, where 0 reflects no LARS and 30-42 major LARS.
Oncological outcome survival60 monthsSurvival in months
Oncological outcome recurrence60 monthsTime to recurrence in months
Prognostic significance of ctDNA60 monthscopies/mL plasma or % fractional abundance (mutant/total ctDNA)
Prognostic significance of CTCs60 monthsCTC/ml blood

Countries

Norway

Contacts

STUDY_DIRECTORKristin B. Lygre, M.D

Haraldsplass Deaconess Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026